Free Trial

Vanda Pharmaceuticals (VNDA) SEC Filings & 10K Form

$5.02
-0.06 (-1.18%)
(As of 09/6/2024 ET)

Recent Vanda Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/08/2024
6:47 AM
Vanda Pharmaceuticals (Filer)
Form 8-A12B/A
08/08/2024
6:29 AM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
6:01 AM
Vanda Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2024
3:05 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2024
4:21 PM
Moran Kevin Patrick (Reporting)
Vanda Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/29/2024
4:24 PM
Moran Kevin Patrick (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
3:38 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/06/2024
3:30 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
3:43 PM
Chrousos Phaedra (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
3:49 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/21/2024
3:52 PM
Vanda Pharmaceuticals (Issuer)
Ward Anne Sempowski (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2024
3:53 PM
Mitchell Stephen Ray (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2024
3:53 PM
DUGAN RICHARD W (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2024
3:55 PM
Honore Tage (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2024
3:34 PM
Vanda Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/20/2024
4:26 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2024
4:15 PM
Vanda Pharmaceuticals (Filer)
Form DEFA14A
05/09/2024
6:07 AM
Vanda Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2024
3:51 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
5:17 AM
Vanda Pharmaceuticals (Filer)
Form DEF 14A
04/29/2024
5:26 AM
Vanda Pharmaceuticals (Filer)
Form ARS
04/17/2024
4:26 PM
Vanda Pharmaceuticals (Filer)
Form 8-A12B
04/17/2024
4:19 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2024
3:32 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/07/2024
3:31 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
3:48 PM
Vanda Pharmaceuticals (Issuer)
Wijkstrom Joakim (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
3:50 PM
Vanda Pharmaceuticals (Issuer)
Williams Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
8:06 PM
Birznieks Gunther (Reporting)
Vanda Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
8:08 PM
Moran Kevin Patrick (Reporting)
Vanda Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
8:10 PM
Polymeropoulos Mihael Hristos (Reporting)
Vanda Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
8:12 PM
Vanda Pharmaceuticals (Subject)
Wijkstrom Joakim (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
8:14 PM
Vanda Pharmaceuticals (Subject)
Williams Timothy (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/21/2024
3:50 PM
Birznieks Gunther (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2024
3:52 PM
Polymeropoulos Mihael Hristos (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2024
3:52 PM
Moran Kevin Patrick (Reporting)
Vanda Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2024
3:52 PM
Vanda Pharmaceuticals (Issuer)
Wijkstrom Joakim (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/21/2024
3:53 PM
Vanda Pharmaceuticals (Issuer)
Williams Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
3:31 PM
Vanda Pharmaceuticals (Filer)
Form 8-K/A
02/13/2024
9:53 AM
RENAISSANCE TECHNOLOGIES LLC (Filed by)
Vanda Pharmaceuticals (Subject)
Form SC 13G/A
02/08/2024
6:19 AM
Vanda Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/05/2024
3:34 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
War on Elon Escalates… (Ad)

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.
01/23/2024
10:52 AM
BlackRock Inc. (Filed by)
Vanda Pharmaceuticals (Subject)
Form SC 13G/A
01/22/2024
10:26 AM
STATE STREET CORP (Filed by)
Vanda Pharmaceuticals (Subject)
Form SC 13G/A
12/07/2023
4:19 PM
Vanda Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/09/2023
6:04 AM
Vanda Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/06/2023
1:34 PM
BlackRock Inc. (Filed by)
Vanda Pharmaceuticals (Subject)
Form SC 13G/A
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:VNDA) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners